The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Pathological vs radiological response in neoadjuvant immunotherapy for HCC
Antonio D’Alessio, MD, Imperial College London, London, UK, discusses a follow-up analysis of the NeoHCC academic consortium, a global academic collaboration investigating neoadjuvant immunotherapy for hepatocellular carcinoma (HCC). The primary analysis established a link between major pathological response and improved relapse-free survival (RFS). However, the follow-up highlights a key challenge: a mismatch between pathological and radiological response when assessing immune checkpoint inhibitors. Additionally, pathological response demonstrated a stronger correlation with RFS than radiological response when assessing immune checkpoint inhibitors, underscoring the need for refined trial endpoints in future HCC immunotherapy studies. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
